1. Home
  2. BLNK vs SCLX Comparison

BLNK vs SCLX Comparison

Compare BLNK & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.70

Market Cap

99.2M

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$9.11

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
SCLX
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.2M
90.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BLNK
SCLX
Price
$0.70
$9.11
Analyst Decision
Buy
Hold
Analyst Count
7
1
Target Price
$2.13
N/A
AVG Volume (30 Days)
3.4M
80.8K
Earning Date
03-12-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,631,000.00
$40,360,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$17.87
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$3.60
52 Week High
$2.65
$34.27

Technical Indicators

Market Signals
Indicator
BLNK
SCLX
Relative Strength Index (RSI) 39.95 37.29
Support Level $0.64 $7.82
Resistance Level $0.72 $10.41
Average True Range (ATR) 0.06 1.02
MACD -0.01 0.07
Stochastic Oscillator 21.10 26.93

Price Performance

Historical Comparison
BLNK
SCLX

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: